Sansure Biotech Inc (688289) - Net Assets

Latest as of June 2026: CN¥7.07 Billion CNY ≈ $1.04 Billion USD

Based on the latest financial reports, Sansure Biotech Inc (688289) has net assets worth CN¥7.07 Billion CNY (≈ $1.04 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.64 Billion ≈ $1.41 Billion USD) and total liabilities (CN¥2.56 Billion ≈ $374.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 688289 equity financing ratio to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥7.07 Billion
% of Total Assets	73.41%
Annual Growth Rate	60.57%
5-Year Change	162.43%
10-Year Change	N/A
Growth Volatility	241.15

Sansure Biotech Inc - Net Assets Trend (2017–2025)

This chart illustrates how Sansure Biotech Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Sansure Biotech Inc stock valuation.

Annual Net Assets for Sansure Biotech Inc (2017–2025)

The table below shows the annual net assets of Sansure Biotech Inc from 2017 to 2025. Also explore net asset momentum of Sansure Biotech Inc to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	CN¥16.75 Billion ≈ $2.45 Billion	+127.98%
2024-12-31	CN¥7.35 Billion ≈ $1.07 Billion	-1.07%
2023-12-31	CN¥7.42 Billion ≈ $1.09 Billion	-1.17%
2022-12-31	CN¥7.51 Billion ≈ $1.10 Billion	+17.73%
2021-12-31	CN¥6.38 Billion ≈ $933.79 Million	+34.47%
2020-12-31	CN¥4.75 Billion ≈ $694.40 Million	+751.23%
2019-12-31	CN¥557.48 Million ≈ $81.58 Million	+40.67%
2018-12-31	CN¥396.29 Million ≈ $57.99 Million	+4.56%
2017-12-31	CN¥378.99 Million ≈ $55.46 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Sansure Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 509789102285.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥4.79 Billion	66.35%
Other Comprehensive Income	CN¥7.13 Billion	98.76%
Total Equity	CN¥7.22 Billion	100.00%

Sansure Biotech Inc Competitors by Market Cap

The table below lists competitors of Sansure Biotech Inc ranked by their market capitalization.

Company	Market Cap
PM Capital Global Opportunities Fund Ltd AU:PGF	$1.40 Billion
Clearway Energy Inc NYSE:CWEN-A	$1.40 Billion
Parade Technologies Ltd TWO:4966	$1.40 Billion
Better Life Commercial Chain Share Co Ltd SHE:002251	$1.40 Billion
Central Plaza Hotel Public Company Limited BK:CENTEL-R	$1.40 Billion
Arlo Technologies NYSE:ARLO	$1.40 Billion
Neway CNC Equipment Suzhou Co Ltd SHG:688697	$1.40 Billion
Wolverine World Wide Inc NYSE:WWW	$1.40 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sansure Biotech Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 7,243,225,866 to 7,220,090,000, a change of -23,135,866 (-0.3%).
Net income of 198,149,400 contributed positively to equity growth.
Dividend payments of 333,680,980 reduced retained earnings.
Other comprehensive income increased equity by 7,130,764,000.
Other factors decreased equity by 7,018,368,286.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥198.15 Million	+2.74%
Dividends Paid	CN¥333.68 Million	-4.62%
Other Comprehensive Income	CN¥7.13 Billion	+98.76%
Other Changes	CN¥-7.02 Billion	-97.21%
Total Change	CN¥-	-0.32%

Book Value vs Market Value Analysis

This analysis compares Sansure Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.34x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 15.75x to 1.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥1.06	CN¥16.63	x
2018-12-31	CN¥1.10	CN¥16.63	x
2019-12-31	CN¥1.05	CN¥16.63	x
2020-12-31	CN¥8.59	CN¥16.63	x
2021-12-31	CN¥10.82	CN¥16.63	x
2022-12-31	CN¥12.82	CN¥16.63	x
2023-12-31	CN¥12.28	CN¥16.63	x
2024-12-31	CN¥12.35	CN¥16.63	x
2025-12-31	CN¥12.39	CN¥16.63	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sansure Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 2.74%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 12.02%
• Asset Turnover: 0.17x
• Equity Multiplier: 1.32x
Recent ROE (2.74%) is below the historical average (14.86%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	-2.81%	-4.74%	0.40x	1.49x	CN¥-48.55 Million
2018	1.71%	2.23%	0.55x	1.39x	CN¥-32.87 Million
2019	7.08%	10.80%	0.57x	1.15x	CN¥-16.27 Million
2020	55.14%	54.94%	0.87x	1.15x	CN¥2.14 Billion
2021	35.21%	49.68%	0.64x	1.11x	CN¥1.61 Billion
2022	25.82%	30.03%	0.70x	1.22x	CN¥1.19 Billion
2023	5.05%	36.12%	0.12x	1.17x	CN¥-356.41 Million
2024	3.80%	18.90%	0.17x	1.19x	CN¥-448.73 Million
2025	2.74%	12.02%	0.17x	1.32x	CN¥-523.86 Million

Industry Comparison

This section compares Sansure Biotech Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

Industry: Medical Instruments & Supplies
Average net assets among peers: $1,290,495,654
Average return on equity (ROE) among peers: 2.68%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Sansure Biotech Inc (688289)	CN¥7.07 Billion	-2.81%	0.36x	$1.40 Billion
Beijing Centergate Technologies Holding Co Ltd (000931)	$1.67 Billion	-1.81%	1.12x	$516.87 Million
Blue Sail Medical Co Ltd (002382)	$1.30 Billion	13.93%	0.22x	$878.76 Million
Andon Health Co Ltd (002432)	$779.96 Million	3.04%	0.05x	$4.39 Billion
Allmed Medical Products Co Ltd Class A (002950)	$3.21 Billion	3.44%	0.58x	$799.71 Million
Guangzhou Improve Med Instrument (300030)	$930.46 Million	4.28%	0.55x	$313.09 Million
QITIAN Technology Group Co Ltd (300061)	$783.38 Million	-63.24%	1.08x	$684.66 Million
Shanghai Tofflon Science Tech (300171)	$2.41 Billion	11.06%	0.57x	$1.77 Billion
Truking Technology Ltd (300358)	$320.32 Million	29.77%	1.35x	$968.97 Million
Jiangxi Sanxin Medtec Co Ltd (300453)	$978.79 Million	15.93%	0.44x	$695.98 Million
Shenyang Xingqi Pharmaceutical Co Ltd (300573)	$520.95 Million	10.42%	0.38x	$1.34 Billion

About Sansure Biotech Inc

SHG:688289 China Medical Instruments & Supplies

Market Cap

$1.40 Billion

CN¥9.56 Billion CNY

Market Cap Rank

#7580 Global

#1687 in China

Share Price

CN¥16.63

Change (1 day)

+0.60%

52-Week Range

CN¥13.87 - CN¥22.12

All Time High

CN¥81.40